【摘要】：目的:探討溫腎活血湯對老年慢性心衰陽虛血瘀證患者活動耐量的改善作用,及對N末端B型利鈉肽原(NT-proBNP),和肽素,心肌肌鈣蛋白T(CTnT)和血漿糖類抗原125(CA125)水平的影響。方法:將158例患者隨機分為對照組和觀察組。對照組在調(diào)整生活方式的基礎(chǔ)上口服復方卡托普利片,2片/次,3次/d;阿替洛爾片,12.5 mg/次,2次/d;螺內(nèi)酯片,10 mg/次,1次/d;地高辛片,0.125 mg/次,必要時服用。觀察組在對照組治療的基礎(chǔ)上加服溫腎活血湯,1劑/d。兩組療程均為16周�；顒幽土坎捎�6 min步行試驗(6 MWT),于治療前、治療后8周和16周各評價1次;生活質(zhì)量采用明尼蘇達心衰生活質(zhì)量調(diào)查表(MLHFQ)和簡明健康問卷(SF-36),治療前后各評價1次;進行治療前后Lee氏心衰評分,NYHA心功能分級和中醫(yī)證候評分;采用超聲心動圖記錄治療前后左室射血分數(shù)(LVEF),心輸出量(CO),左室收縮末內(nèi)徑(LVESD)和舒張早期血流峰值(E)和舒張晚期血流峰值(A)之比(E/A),檢測治療前后NT-proBNP,和肽素,CTn T和CA125水平。結(jié)果:觀察組心功能療效總有效率為88.73%,高于對照組的71.43%(χ~2=6.631,P0.05);觀察組心衰療效總有效率為85.92%,高于對照組的67.14%(χ~2=6.929,P0.01);觀察組在治療后8周和16周,6 min步行距離均多于對照組(P0.01);觀察組SF-36量表各維度評分均較對照組高(P0.01);治療后觀察組Lee氏心衰,MLHFQ,陽虛血瘀證和NYHA心功能分級評分均低于對照組(P0.01);治療后觀察組LVEF,CO和E/A均高于對照組(P0.05,P0.01);治療后觀察組NT-proBNP,CTnT,CA125和和肽素水平低于對照組(P0.01)。結(jié)論:溫腎活血湯治療老年CHF陽虛血瘀證患者,能減輕心衰癥狀,改善心功能,并能調(diào)節(jié)NT-proBNP,CTnT,CA125和和肽素水平,起到提高患者活動耐量和生活質(zhì)量的作用。
[Abstract]:Objective: to investigate the effect of Wenshen Huoxue decoction (WXD) on the activity tolerance of elderly patients with chronic heart failure with yang deficiency and blood stasis syndrome, and to study the effect of warming kidney and activating blood decoction on N-terminal B-type natriuretic peptide (NT-proBNP) and peptide. Effects of cardiac troponin T (CTnT) and plasma carbohydrate antigen 125 (CA125) levels. Methods: 158 patients were randomly divided into control group and observation group. The control group was treated with compound captopril tablets (2 tablets, 3 times per day), atenolol tablets (12. 5 mg/, 2 times per day), spironolactone tablets (10 mg/, 1 time per day), while the control group took compound captopril tablets once a day on the basis of lifestyle adjustment. Digoxin tablets, 0.125 mg/, if necessary. The observation group was treated with Wenshen Huoxue decoction, 1 dose per day. The course of treatment in both groups was 16 weeks. The activity tolerance was measured by 6 min walking test (6 MWT), before treatment, 8 weeks and 16 weeks after treatment respectively). The quality of life (QOL) was evaluated once before and after treatment by Minnesota Heart failure questionnaire (MLHFQ) and brief Health questionnaire (SF-36). Lee's heart failure score, NYHA cardiac function grading and TCM syndromes score were performed before and after treatment. Left ventricular ejection fraction (LVEF),) cardiac output (CO), left ventricular end-systolic diameter (LVESD), early diastolic peak value (E) and late diastolic peak value (A) ratio (E / A) were recorded by echocardiography before and after treatment. The levels of NT-proBNP, CTn T and CA125 were measured before and after treatment. Results: the total effective rate of cardiac function in the observation group was 88.73, which was higher than that in the control group (71.43%) (蠂 ~ 2, 6.631, P 0.05). The total effective rate of heart failure in the observation group was 85.92, which was higher than that in the control group (67.14%), and the walking distance in the observation group at 8 and 16 weeks after treatment was higher than that in the control group (P0.01). The scores of each dimension of SF-36 scale in the observation group were higher than those in the control group (P0.01), the scores of Lee's heart failure, MLHFQ, yang deficiency and blood stasis syndrome and NYHA cardiac function grading in the observation group were lower than those in the control group after treatment (P0.01). After treatment, the levels of LVEF,CO and EPA in the observation group were higher than those in the control group (P 0.05 P 0.01), and the levels of NT-proBNP,CTnT,CA125 and peptide in the observation group were lower than those in the control group (P 0.01). Conclusion: Wenshen Huoxue decoction can relieve the symptoms of heart failure, improve cardiac function, regulate the levels of NT-proBNP,CTnT,CA125 and peptide, and improve the activity tolerance and quality of life in the elderly patients with CHF syndrome of yang deficiency and blood stasis.
【作者單位】： 重慶市中醫(yī)院;
【基金】：重慶市科技計劃項目(cste2016jcyjAX0010)
【分類號】：R259

【相似文獻】

相關(guān)期刊論文 前7條

1 鄭小偉;李巍;;陽虛血瘀證凝血機制異常動物模型的實驗研究[J];吉林中醫(yī)藥;1993年03期

2 周慎,楊維華,劉芳,李佑生,伍大華,楊力;溫腎健腦法對腦萎縮腎陽虛血瘀證患者主癥及智能狀態(tài)的影響[J];中國中醫(yī)藥科技;2004年02期

3 王昀;季蓓;王tq;;通窄飲治療冠脈介入術(shù)后陽虛血瘀證的臨床研究[J];中國中醫(yī)藥科技;2012年06期

4 張?zhí)N慧;;心痛寧膠囊治療冠狀動脈痙攣陽虛血瘀證臨床觀察[J];山東中醫(yī)雜志;2011年06期

5 張明雪;劉寧;常艷鵬;林巾孝;;溫陽活血中藥復方對冠心病陽虛血瘀證大鼠血小板超微結(jié)構(gòu)及聚集率的影響[J];中國中醫(yī)急癥;2008年04期

6 張?zhí)N慧;;心痛寧膠囊治療冠狀動脈痙攣陽虛血瘀證患者高敏C反應(yīng)蛋白水平的觀察[J];中西醫(yī)結(jié)合心腦血管病雜志;2012年03期

7 ;[J];;年期

相關(guān)重要報紙文章 前1條

1 指導專家 上海中醫(yī)藥大學附屬市中醫(yī)醫(yī)院中醫(yī)骨傷科 裘敏蕾 副主任醫(yī)師 趙非一;中醫(yī)療“骨松” 從腎入手，，針藥并用[N];上海中醫(yī)藥報;2014年

相關(guān)博士學位論文 前1條

1 常佩芬;心衰康治療冠心病心衰陽虛血瘀證的臨床研究[D];北京中醫(yī)藥大學;2005年

相關(guān)碩士學位論文 前9條

1 王詩瑤;溫陽活血法治療冠心病心絞痛（陽虛血瘀證）的臨床研究[D];遼寧中醫(yī)藥大學;2016年

2 常艷鵬;冠心病陽虛血瘀證病證結(jié)合研究[D];遼寧中醫(yī)藥大學;2008年

3 高海軍;復方交泰丸干預(yù)慢性腎心綜合征陽虛血瘀證的臨床研究[D];河南中醫(yī)學院;2015年

4 汪艷麗;通陽活血方治療慢性充血性心力衰竭陽虛血瘀證的臨床研究[D];中國中醫(yī)科學院;2010年

5 李倩;當歸四逆湯加減方治療老年下肢動脈粥樣硬化疾病陽虛血瘀證的臨床研究[D];南京中醫(yī)藥大學;2011年

6 鄧定偉;溫陽活血方對冠心病介入術(shù)后陽虛血瘀證患者的影響[D];廣州中醫(yī)藥大學;2009年

7 劉寧;溫陽活血中藥復方調(diào)控冠心病血小板內(nèi)受體—配體、信號轉(zhuǎn)導的作用機理研究[D];遼寧中醫(yī)藥大學;2008年

8 帥云飛;溫腎活血通脈片治療冠心病穩(wěn)定型心絞痛之陽虛血瘀證的臨床觀察[D];湖南中醫(yī)藥大學;2009年

9 王佳笑;基于中醫(yī)結(jié)構(gòu)化住院病歷數(shù)據(jù)的糖尿病合并高血壓病證結(jié)合診療規(guī)律探討[D];中國中醫(yī)科學院;2014年

本文編號：2336148